Eschew Enhancement: Memory-Boosting Drugs Should Not Be Made Available to the General Public

In an effort to provide Alzheimer's and schizophrenia patients with better, safer medicines, biotech and big pharma have embarked on drug discovery programs targeting multiple cognitive mechanisms. For patients suffering from these diseases, the new drugs have the potential to improve cognitive function over a longer term than available treatments, which fade in effectiveness over time. Yet given the leaky and lucrative electronic trade in prescription drugs, it's likely that these medicines will also be available to healthy people who hope to benefit from them as well. MIT Technology Review